Assessment of orally administered Pistacia atlantica gum medicine in the treatment of gastrointestinal disease

Not Applicable

Recruiting

• Conditions: Condition 1: Peptic ulcer. Condition 2: Peptic ulcer.; Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation; K27.9; Peptic ulcer, site unspecified

• Registration Number: IRCT20130313012810N4
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Urease positive peptic ulcer suffering patients

Exclusion Criteria

Pregnant and lactating women
Known cases of gastric ulcer and malignant duodenal ulcer
Patients taking nonsteroidal anti-inflammatory drugs (NSAIDs), blood thinners, or antibiotics 4 weeks before the urease breath test
Patients who received a combination of bismuth 2 weeks before the urea test
Patients receiving proton pump inhibitors or any antacids 3 days before the urease breath test

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of patients converting urease test positive to negative. Timepoint: 14 days after starting to use Pistacia atlantica gum soft gelatin capsule. Method of measurement: Measurement of CO2 in exhalation by carbon analyzer.